-
Vorolanib Tablets Approved for Marketing by China NMPA
2023-06-08
Recently, the Category 1 innovative drug Vorolanib Tablets (Chinese trade name: 伏美纳) of Betta Pharmaceuticals Co., Ltd is approved by China NMPA.
-
Innovative TCM Shenyu Ningshen Tablet Approved for Marketing by China NMPA
2023-06-08
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Shenyu Ningshen Tablets of Guangdong Siji Pharmaceutical Co., Ltd was approved for marketing by China NMPA.
-
Rules for Labels of Prepared Slices of Chinese Crude Drugs Issued by China NMPA
2023-07-14
The NMPA organized to formulate the Rules for Labels of Prepared Slices of Chinese Crude Drugs, which is hereby released and shall be implemented since August 1, 2024.
-
Befotertinib Mesylate Capsules Approved for Marketing
2023-05-31
Recently, the Class I innovative product Befotertinib Mesylate Capsules (Chinese trade name: 赛美纳) of Betta Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Alfosbuvir Tablets Approved for Marketing
2023-05-17
Recently, the Class-1 innovative drug Alfosbuvir Tablets (Chinese trade name:圣诺迪) of Nanjing Sanhome Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Zuberitamab Injection Approved for Marketing
2023-05-17
Recently, the Zuberitamab injection (Chinese trade name: 安瑞昔) of Zhejiang BioRay Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of CD20 positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) for adult patients, and should be combined with standardized CHOP therapies (cyclophosphamide, doxorubicin, vincristine, prednisone).
